<DOC>
	<DOCNO>NCT02391194</DOCNO>
	<brief_summary>This Phase 1 , open-label , dose escalation study woman primary , non-recurrent breast cancer undergo surgery . AVB-620 administer prior surgery .</brief_summary>
	<brief_title>Trial AVB-620 Women With Primary , Non-Recurrent Breast Cancer Undergoing Surgery</brief_title>
	<detailed_description>This study examine safety tolerability AVB-620 administer IV infusion woman primary , non-recurrent breast cancer undergo surgery . The study also characterize pharmacokinetics AVB-620 subject population determine dose AVB-620 needed generate fluorescence signal tumor lymph node tissue enable fluorescence recording image analysis image system . The study also evaluate effect time AVB-620 administration , relative surgery , fluorescence characteristic .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Ductal carcinoma situ ( DCIS ) Stage IIII , primary invasive carcinoma breast Primary surgical treatment plan mastectomy lumpectomy . Sentinel lymph node ( LN ) biopsy axillary LN dissection ( ALND ) plan part subject 's therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate renal function Lab value ( hematology chemistry ) within institution 's normal laboratory limit Willing remain onsite approximately 24 hour administration AVB620 , require , stay overnight surgical procedure If subject receive neoadjuvant therapy , residual tumor present ( determined primary surgeon ) If subject receive prior anthracycline therapy , leave ventricular ejection fraction ( LVEF ) must within institution 's normal limit Subject ability understand willingness sign write informed consent document Recurrent ipsilateral breast cancer Prior neoadjuvant chemotherapy biologic therapy current clinically biopsyproven node positive breast cancer within 4 week plan surgery . Open surgery ipsilateral breast within 1 year AVB620 administration History radiation therapy ipsilateral breast Abnormal cardiac rhythm control medication , history stroke , coronary event , and/or heart failure within 1 year AVB620 administration Diagnosis autoimmune disorder History drugrelated anaphylactic reaction allergic reaction ; subject active diagnosis uncontrolled airway hyperactivity , uncontrolled asthma , asthma require oral corticosteroid exclude History renal disease current evidence renal disease Current diagnosis active clinically significant nonbreast cancer Systemic investigational drug kind within 6 week AVB620 administration Pregnant breast feeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AVB-620</keyword>
	<keyword>stage I</keyword>
	<keyword>newly diagnose</keyword>
	<keyword>breast cancer</keyword>
	<keyword>stage II</keyword>
	<keyword>stage III</keyword>
	<keyword>ductal carcinoma situ</keyword>
</DOC>